Versor Investments LP Has $638,000 Position in Zoetis Inc. (NYSE:ZTS)

Versor Investments LP boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 26.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,263 shares of the company’s stock after buying an additional 683 shares during the period. Versor Investments LP’s holdings in Zoetis were worth $638,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. First Personal Financial Services acquired a new position in Zoetis during the 3rd quarter valued at about $33,000. Capital Performance Advisors LLP bought a new stake in Zoetis during the third quarter worth $33,000. Quarry LP lifted its stake in Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after acquiring an additional 153 shares in the last quarter. LRI Investments LLC purchased a new position in Zoetis during the 1st quarter worth $43,000. Finally, Fortitude Family Office LLC grew its stake in shares of Zoetis by 1,387.5% in the 3rd quarter. Fortitude Family Office LLC now owns 238 shares of the company’s stock worth $46,000 after acquiring an additional 222 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ZTS. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Argus upgraded Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Stifel Nicolaus increased their price target on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Stock Performance

Shares of ZTS stock opened at $177.28 on Thursday. The firm’s 50 day moving average is $187.81 and its 200 day moving average is $180.04. The stock has a market capitalization of $79.98 billion, a P/E ratio of 33.00, a PEG ratio of 2.67 and a beta of 0.90. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter in the prior year, the business posted $1.36 earnings per share. The business’s quarterly revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date of this dividend is Thursday, October 31st. Zoetis’s payout ratio is 32.52%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.